Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients

Ilham Youssry1, Nohair Soliman2, Mona Ghamrawy3

  • 1Departments of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt. ilhamyoussry@yahoo.com.

Annals of Hematology
|February 8, 2017
PubMed

Insights

Elevated circulating microparticles (MPs) increase the risk of thromboembolic events (TEEs) in thalassemia patients. This study found higher MP levels in patients with TEEs, identifying key predictive factors for these dangerous complications.

Area of Science:

  • Hematology
  • Vascular Biology
  • Thrombosis Research

Background:

  • Thalassemia patients are prone to thromboembolic events (TEEs).
  • Circulating microparticles (MPs) are implicated in TEE pathogenesis.
  • Differences in MP levels between β-thalassemia major (β-TM) and thalassemia intermedia (TI) are not well-established.

Purpose of the Study:

  • To evaluate circulating MPs and thrombotic risk in thalassemia patients.
  • To compare MP levels between β-TM and TI.
  • To identify independent risk factors for TEEs in this population.

Main Methods:

  • Flow cytometry was used to measure annexin-labeled MPs, platelet-derived MPs (PMPs), erythrocyte-derived MPs (RMPs), and endothelial-derived MPs (EMPs).
  • 87 thalassemia patients (39 β-TM, 48 TI) were analyzed.
  • Multiple regression analysis identified risk factors for TEEs.

Main Results:

  • Thalassemia patients with TEEs showed significantly higher platelet counts, overall MPs, and PMPs.
  • No significant differences in MP levels were observed between β-TM and TI patients.
  • Splenectomy, bilirubin levels, RMPs, and EMPs were identified as predictive risk factors for TEEs.

Conclusions:

  • Elevated circulating MPs are a significant risk factor for TEEs in thalassemia patients.
  • Specific MP types and clinical factors contribute to TEE risk.
  • Further research into MP-targeted therapies may be warranted.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432